Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American ...
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
A study published Wednesday indicates that low levels of a key brain chemical among overweight patients with high-fat diets ...
Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...
Explore more
Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...
Natixis Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 4.5% during the 4th quarter, HoldingsChannel reports. The fund owned 10,453 shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results